Stock TVTX TRAVERE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Real-time Estimate Cboe BZX
Other stock markets
 02:01:04 2024-04-19 pm EDT 		5-day change 1st Jan Change
5.655 USD -2.50% Intraday chart for Travere Therapeutics, Inc. -10.75% -36.76%
Apr. 03 Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association CI
Mar. 28 North American Morning Briefing : Stocks Set for -2- DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
GL
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
GL
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association
CI
North American Morning Briefing : Stocks Set for -2-
DJ
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Transcript : Travere Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy
MT
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
GL
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy
CI
Travere Therapeutics to Present at Upcoming Investor Conferences
GL
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
AQ
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease
MT
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
GL
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy
CI
Travere drug for rare kidney condition recommended for EU approval
RE
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
PR
Transcript : Travere Therapeutics, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q4 Revenue $45.1M, vs. Street Est of $41.8M
MT
Travere: Q4 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TVTX Stock
  4. News Travere Therapeutics, Inc.